세계의 급성 편두통 치료 시장 보고서(2025년)

Acute migraine treatments involve therapies aimed at providing immediate relief from migraine attacks by addressing symptoms such as intense headaches, nausea, and heightened sensitivity to light and sound. These treatments are designed to reduce the severity and duration of migraines, improving patient comfort and functionality during episodes.

The primary types of drugs used for acute migraine treatment include triptans, calcitonin gene-related peptide (CGRP) antagonists, nonsteroidal anti-inflammatory drugs (NSAIDs), beta-adrenergic blockers, ergot alkaloids, and others. Triptans are medications that specifically target serotonin 1B and 1D receptors, leading to vasoconstriction and reducing the release of inflammatory substances. They are considered specific treatments for migraines and are commonly used for acute relief. These medications can be administered orally, through injection, or by other methods and are available through various distribution channels, including hospital pharmacies, retail pharmacies, drug stores, and online platforms.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The acute migraine treatments market research report is one of a series of new reports from The Business Research Company that provides acute migraine treatments market statistics, including acute migraine treatments industry global market size, regional shares, competitors with an acute migraine treatments market share, detailed acute migraine treatments market segments, market trends, and opportunities, and any further data you may need to thrive in the acute migraine treatments industry. This acute migraine treatments research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The acute migraine treatment market size has grown rapidly in recent years. It will grow from $2.6 billion in 2024 to $2.9 billion in 2025 at a compound annual growth rate (CAGR) of 11.3%. The growth in the historic period can be attributed to the increasing prevalence of migraine, growth of specialty clinics, increasing funding for migraine research, growth in clinical trials, and increasing use of preventive medications.

The acute migraine treatment market size is expected to see rapid growth in the next few years. It will grow to $4.41 billion in 2029 at a compound annual growth rate (CAGR) of 11.1%. The growth in the forecast period can be attributed to the increasing prevalence of migraine, growing investment in migraine research, rising demand for non-invasive treatment options, rising demand for quick-acting relief options, and growing emphasis on patient-centric drug development. Major trends in the forecast period include technological advancements, the adoption of neuromodulation devices, personalized medicine, telemedicine, and diagnostic tools.

The forecast of 11.1% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. The U.S. neurology market may see reduced affordability as tariffs increase the cost of Calcitonin gene-related peptide(CGRP) inhibitors and nerve block supplies sourced from Ireland and Denmark, limiting access to breakthrough therapies for migraine sufferers. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The growing work pressure is anticipated to drive the growth of the acute migraine treatment market moving forward. Work pressure refers to the mental, emotional, and physical strain that employees experience due to the demands and challenges of their job roles. Contributing factors to the increase in work pressure include tight deadlines, insufficient resources and support, poor work-life balance, unclear job roles, interpersonal conflicts, and organizational changes. Acute migraine treatment for heightened work pressure focuses on managing migraine symptoms that may be triggered or worsened by stress, particularly in demanding work environments. For example, in October 2022, the American Psychological Association, a US-based association of psychologists, reported that workplace stress remains a significant issue, with 77% of employees experiencing work-related stress in the past month. Furthermore, 57% of employees mentioned suffering negative effects, such as emotional exhaustion (31%), often associated with workplace burnout. Hence, the increasing work pressure is fueling the growth of the acute migraine treatment market.

Leading companies in the acute migraine treatment market are focused on developing innovative solutions, such as nasal sprays, to improve the effectiveness and convenience of migraine relief. Migraine nasal sprays administer medication through the nasal passages, offering the benefit of rapid absorption and quicker relief compared to oral medications. For example, in March 2023, Pfizer Inc., a US-based biotechnology company, introduced ZAVZPRET (zavegepant) Migraine Nasal Spray, approved by the FDA. This nasal spray uses zavegepant, a CGRP receptor antagonist, to block the calcitonin gene-related peptide (CGRP) pathway, providing swift and targeted relief from migraines. ZAVZPRET's fast-acting formulation offers relief within 15 minutes, making it a convenient choice for those seeking quick relief from severe migraine symptoms.

In October 2022, Pfizer Inc. acquired Biohaven Pharmaceutical Holding Company Ltd. for $11.6 billion. This acquisition aims to enhance Pfizer's position in the neurology and pain management sectors by integrating Biohaven's innovative migraine treatments and other neurological therapies. Biohaven Pharmaceutical Holding Company Ltd. specializes in treatments for acute migraines.

Major companies operating in the acute migraine treatment market are Pfizer Inc., Johnson And Johnson, Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Viatris Inc., Allergan plc, Teva Pharmaceutical Industries Ltd., Bausch Health Companies Inc., Endo International plc, Supernus Pharmaceuticals Inc., Collegium Pharmaceutical Inc., Upsher-Smith Laboratories LLC, BioDelivery Sciences International Inc., Axsome Therapeutics Inc., Impel NeuroPharma Inc., Currax Pharmaceuticals LLC, Satsuma Pharmaceuticals Inc.

North America was the largest region in the acute migraine treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acute migraine treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the acute migraine treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The acute migraine treatment market consists of revenues earned by entities by providing emergency room (ER) services, headache centers, primary care physicians, and pain management. The market value includes the value of related goods sold by the service provider or included within the service offering. The acute migraine treatment market also includes sales of acetaminophen, anti-nausea medications, CGRP antagonists, and transcranial magnetic stimulation (TMS) devices. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Acute Migraine Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on acute migraine treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for acute migraine treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The acute migraine treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Type: Triptans; Calcitonin Gene-Related Peptide Antagonist; Nonsteroidal Anti-Inflammatory Drugs; Beta-Adrenergic; Ergot Alkaloids; Other Drug Types
• 2) By Route Of Administration: Oral; Injection; Other Routes Of Administration
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Drug Stores; E-Commerce
• Subsegments:
• 1) By Triptans: Sumatriptan; Rizatriptan; Zolmitriptan; Eletriptan
• 2) By Calcitonin Gene-Related Peptide (CGRP) Antagonists: Erenumab; Fremanezumab; Galcanezumab
• 3) By Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Ibuprofen; Naproxen; Diclofenac
• 4) By Beta-Adrenergic: Propranolol; Metoprolol; Atenolol
• 5) By Ergot Alkaloids: Ergotamine; Dihydroergotamine
• 6) By Other Drug Types: Antiemetic Drugs; Antidepressants; Corticosteroids
• Companies Mentioned: Pfizer Inc.; Johnson And Johnson; Hoffmann-La Roche Ltd.; Merck & Co. Inc.; AbbVie Inc.; AstraZeneca PLC; Novartis AG; GlaxoSmithKline plc; Eli Lilly and Company; Amgen Inc.; Viatris Inc.; Allergan plc; Teva Pharmaceutical Industries Ltd.; Bausch Health Companies Inc.; Endo International plc; Supernus Pharmaceuticals Inc.; Collegium Pharmaceutical Inc.; Upsher-Smith Laboratories LLC; BioDelivery Sciences International Inc.; Axsome Therapeutics Inc.; Impel NeuroPharma Inc.; Currax Pharmaceuticals LLC; Satsuma Pharmaceuticals Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Acute Migraine Treatment Market Characteristics

3. Acute Migraine Treatment Market Trends And Strategies

4. Acute Migraine Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

• 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Acute Migraine Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Acute Migraine Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Acute Migraine Treatment Market Growth Rate Analysis
• 5.4. Global Acute Migraine Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Acute Migraine Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Acute Migraine Treatment Total Addressable Market (TAM)

6. Acute Migraine Treatment Market Segmentation

• 6.1. Global Acute Migraine Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Triptans
• Calcitonin Gene-Related Peptide Antagonist
• Nonsteroidal Anti-Inflammatory Drugs
• Beta-Adrenergic
• Ergot Alkaloids
• Other Drug Types
• 6.2. Global Acute Migraine Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Injection
• Other Routes Of Administration
• 6.3. Global Acute Migraine Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Drug Stores
• E-Commerce
• 6.4. Global Acute Migraine Treatment Market, Sub-Segmentation Of Triptans, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Sumatriptan
• Rizatriptan
• Zolmitriptan
• Eletriptan
• 6.5. Global Acute Migraine Treatment Market, Sub-Segmentation Of Calcitonin Gene-Related Peptide (CGRP) Antagonists, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Erenumab
• Fremanezumab
• Galcanezumab
• 6.6. Global Acute Migraine Treatment Market, Sub-Segmentation Of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ibuprofen
• Naproxen
• Diclofenac
• 6.7. Global Acute Migraine Treatment Market, Sub-Segmentation Of Beta-Adrenergic, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Propranolol
• Metoprolol
• Atenolol
• 6.8. Global Acute Migraine Treatment Market, Sub-Segmentation Of Ergot Alkaloids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ergotamine
• Dihydroergotamine
• 6.9. Global Acute Migraine Treatment Market, Sub-Segmentation Of Other Drug Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antiemetic Drugs
• Antidepressants
• Corticosteroids

7. Acute Migraine Treatment Market Regional And Country Analysis

• 7.1. Global Acute Migraine Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Acute Migraine Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Acute Migraine Treatment Market

• 8.1. Asia-Pacific Acute Migraine Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Acute Migraine Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Acute Migraine Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Acute Migraine Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Acute Migraine Treatment Market

• 9.1. China Acute Migraine Treatment Market Overview
• 9.2. China Acute Migraine Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Acute Migraine Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Acute Migraine Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Acute Migraine Treatment Market

• 10.1. India Acute Migraine Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Acute Migraine Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Acute Migraine Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Acute Migraine Treatment Market

• 11.1. Japan Acute Migraine Treatment Market Overview
• 11.2. Japan Acute Migraine Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Acute Migraine Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Acute Migraine Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Acute Migraine Treatment Market

• 12.1. Australia Acute Migraine Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Acute Migraine Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Acute Migraine Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Acute Migraine Treatment Market

• 13.1. Indonesia Acute Migraine Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Acute Migraine Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Acute Migraine Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Acute Migraine Treatment Market

• 14.1. South Korea Acute Migraine Treatment Market Overview
• 14.2. South Korea Acute Migraine Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Acute Migraine Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Acute Migraine Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Acute Migraine Treatment Market

• 15.1. Western Europe Acute Migraine Treatment Market Overview
• 15.2. Western Europe Acute Migraine Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Acute Migraine Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Acute Migraine Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Acute Migraine Treatment Market

• 16.1. UK Acute Migraine Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Acute Migraine Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Acute Migraine Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Acute Migraine Treatment Market

• 17.1. Germany Acute Migraine Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Acute Migraine Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Acute Migraine Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Acute Migraine Treatment Market

• 18.1. France Acute Migraine Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Acute Migraine Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Acute Migraine Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Acute Migraine Treatment Market

• 19.1. Italy Acute Migraine Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Acute Migraine Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Acute Migraine Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Acute Migraine Treatment Market

• 20.1. Spain Acute Migraine Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Acute Migraine Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Acute Migraine Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Acute Migraine Treatment Market

• 21.1. Eastern Europe Acute Migraine Treatment Market Overview
• 21.2. Eastern Europe Acute Migraine Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Acute Migraine Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Acute Migraine Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Acute Migraine Treatment Market

• 22.1. Russia Acute Migraine Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Acute Migraine Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Acute Migraine Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Acute Migraine Treatment Market

• 23.1. North America Acute Migraine Treatment Market Overview
• 23.2. North America Acute Migraine Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Acute Migraine Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Acute Migraine Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Acute Migraine Treatment Market

• 24.1. USA Acute Migraine Treatment Market Overview
• 24.2. USA Acute Migraine Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Acute Migraine Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Acute Migraine Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Acute Migraine Treatment Market

• 25.1. Canada Acute Migraine Treatment Market Overview
• 25.2. Canada Acute Migraine Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Acute Migraine Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Acute Migraine Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Acute Migraine Treatment Market

• 26.1. South America Acute Migraine Treatment Market Overview
• 26.2. South America Acute Migraine Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Acute Migraine Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Acute Migraine Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Acute Migraine Treatment Market

• 27.1. Brazil Acute Migraine Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Acute Migraine Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Acute Migraine Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Acute Migraine Treatment Market

• 28.1. Middle East Acute Migraine Treatment Market Overview
• 28.2. Middle East Acute Migraine Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Acute Migraine Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Acute Migraine Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Acute Migraine Treatment Market

• 29.1. Africa Acute Migraine Treatment Market Overview
• 29.2. Africa Acute Migraine Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Acute Migraine Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Acute Migraine Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Acute Migraine Treatment Market Competitive Landscape And Company Profiles

• 30.1. Acute Migraine Treatment Market Competitive Landscape
• 30.2. Acute Migraine Treatment Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson And Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Acute Migraine Treatment Market Other Major And Innovative Companies

• 31.1. AstraZeneca PLC
• 31.2. Novartis AG
• 31.3. GlaxoSmithKline plc
• 31.4. Eli Lilly and Company
• 31.5. Amgen Inc.
• 31.6. Viatris Inc.
• 31.7. Allergan plc
• 31.8. Teva Pharmaceutical Industries Ltd.
• 31.9. Bausch Health Companies Inc.
• 31.10. Endo International plc
• 31.11. Supernus Pharmaceuticals Inc.
• 31.12. Collegium Pharmaceutical Inc.
• 31.13. Upsher-Smith Laboratories LLC
• 31.14. BioDelivery Sciences International Inc.
• 31.15. Axsome Therapeutics Inc.

32. Global Acute Migraine Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Acute Migraine Treatment Market

34. Recent Developments In The Acute Migraine Treatment Market

35. Acute Migraine Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Acute Migraine Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Acute Migraine Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Acute Migraine Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer